JJJavier Jaén-Olasolo

Javier Jaén-Olasolo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javier Jaén-Olasolo has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Partial breast irradiation versus whole breast irradiation after breast-conserving surgery in early-stage breast cancer: a systematic review

    by Sara Garduño-Sánchez, María Isabel Villanego-Beltrán, Francisco Javier Carrasco-Sánchez, Juan Gómez-Salgado, Javier Jaén-Olasolo

    Introduction: Adjuvant radiotherapy for early-stage breast cancer has progressively shifted toward less extensive treatment approaches. Partial breast irradiation (PBI) has emerged as a safe and effective option for appropriately selected patients. Aim: To systematically compare PBI versus whole breast irradiation (WBI) in early-stage breast cancer with respect to acute and late toxicity, cosmetic outcomes, quality of life, local disease control, and survival. Methods: We conducted a systematic review of randomized clinical trials evaluating PBI delivered by any technique versus WBI in early-stage breast cancer. Searches were performed in CENTRAL/CCTR, EMBASE, MEDLINE, CINAHL, ISRCTN, and ClinicalTrials.gov, following PRISMA 2020 guidelines. Risk of bias was assessed using the Cochrane RoB 2 tool. Trials with low risk of bias were further evaluated. The CONSORT 2010 statement was used to guide standardized reporting, without influencing study selection. Results: Of 340 records identified, 55 were randomized trials. After applying eligibility criteria and excluding studies with high or unclear risk of bias, 15 low-risk trials were included. Overall, PBI demonstrated comparable oncologic outcomes to WBI, with reduced treatment-related burden and improved quality of life in selected patients. However, results varied by technique and fractionation schedule. Notably, the RAPID trial reported higher rates of acute and late skin toxicity and worse cosmetic outcomes with twice-daily 3D external beam PBI, highlighting the importance of technique optimization and appropriate patient selection. Conclusions: PBI is a safe and effective alternative to WBI in carefully selected patients with early-stage breast cancer, offering meaningful reductions in toxicity and treatment burden without compromising disease control. Technique-specific considerations remain critical to maximizing both clinical and cosmetic outcomes.


  • Open Access

    Long-term outcomes of accelerated partial breast irradiation with multicatheter interstitial brachytherapy versus whole breast irradiation: an 11-Year clinical practice follow-up study

    by Sara Garduño-Sánchez, María Isabel Villanego-Beltrán, Juan Gómez-Salgado, Javier Jaén-Olasolo

    Purpose: To compare the long-term outcomes of accelerated partial breast irradiation (APBI) using multicatheter interstitial brachytherapy versus whole breast irradiation (WBI), in terms of late toxicity, cosmetic results, quality of life, and survival, in a real-world clinical setting. Methods: Updated analysis of two prospectively collected cohorts comprising 76 patients with stage I–II breast cancer treated with breast-conserving surgery followed by adjuvant radiotherapy. Patients who underwent APBI met the GEC-ESTRO eligibility criteria. We assessed follow-up and additional analyses of late toxicity, quality of life (assessed using the validated QLQ-BR23 and S-BIS questionnaires), cosmetic outcomes (via Visual Analog Scale), overall survival (OS), and disease-free survival (DFS), providing a more comprehensive evaluation of long-term outcomes. Results: At a median follow-up of 11 years, patient-reported quality of life remained significantly better in the APBI group, particularly in both physical and psychological domains, consistent with previous findings. No significant differences were observed in late clinical toxicity or cosmetic outcomes between groups. However, late mammographic findings showed a higher incidence of architectural distortion and tissue retraction in the APBI group, confirming earlier observations. The estimated 5- and 10-year OS rates were 94.7 and 81.1%, respectively. Corresponding DFS rates were 92.1% and 79.7%, with no statistically significant differences between treatment groups. Conclusion: With extended follow-up, our results reinforce that APBI using multicatheter interstitial brachytherapy is a safe and effective alternative to WBI in selected patients, providing long-term tumor control and survival comparable to WBI, while offering improved quality of life.


  • High dose rate endoluminal brachytherapy in the treatment of endobronchial lesions — experience of a single institution and literature review

    by María Jesús Macías-Lozano, Verónica Díaz-Díaz, Sarah Sayago-Gil, Cayo García-Polo, Javier Jaén-Olasolo

    Purpose To evaluate the efficacy and toxicity of Iridium-192 high-dose-rate endobronchial brachytherapy (HDR-EBT) for palliation of symptoms and for curative intent. Material and methods This is a retrospective study of a prospectively registered cohort of 31 patients with endobronchial lesions treated with HDR-EBT at our institution between 2008 and 2020. Eighteen patients were treated with palliative intent and 13 curative intent; 4 of them as a boost to external radiation therapy (XRT). The primary objectives of the study were to analyze the symptomatic relief, endoscopic response, and treatment-related toxicity. As a secondary endpoint, survival analyses were performed. Results In palliative setting, most of the symptomatic patients (80%) presented a significant clinical improvement and 75% presented endoscopic improvement of the lesions. In curative setting, all patients with visible lesions had endoscopic improvement and better survival than palliatively treated patients (median: 78 and 9 months, respectively; p = 0.002). There were no complications in 91.4% of the treatments: only one pneumonia, one pneumothorax and one bronchial stenosis occurred, all in palliative treatments. No fatal hemoptysis happened. Acute toxicity was mild (G ≤ 2) and transitory. Discussion HDR-EBT is an excellent, safe, and inexpensive palliative treatment of symptoms caused by endobronchial growth of tumors in the proximal airway, either as a single treatment or in combination with XRT. It can also be an alternative in the treatment of initial malignant tumors when surgery or XRT is not possible, and it may also play a role in treating non-malignant bronchial obstructions.


  • Response to letter to the Editor

    by Sara Garduño-Sánchez, Isabel Villanego-Beltrán, María Dolores de Las Peñas-Cabrera, Javier Jaén-Olasolo

  • Comparison between Accelerated Partial Breast Irradiation with multicatheter interstitial brachytherapy and Whole Breast Irradiation, in clinical practice

    by S. Garduño-Sánchez, I. Villanego-Beltrán, M. Dolores de Las Peñas-Cabrera, J. Jaén-Olasolo

    Purpose The aim of this study was to compare accelerated partial breast irradiation (APBI) with multicatheter interstitial brachytherapy (BT) and whole breast irradiation (WBI), in terms of toxicity, aesthetic result, quality of life and survival, in clinical practice. Materials and methods A comparative study of two prospectively recorded cohorts of 76 breast cancer patients who complied with the recommendations of GEC-ESTRO for APBI was conducted. The main objective was toxicity, quality of life measured through validated questionnaires and the aesthetic results. Secondary objectives were overall survival and disease-free survival. Results Seventy-six stage I/II breast cancer patients, with a mean age of 66 years entered the study. APBI group showed less acute G1-2 dermatitis (51.4 vs 94.9%, p < 0.001) and late hyperpigmentation (0 vs 17.9%, p = 0.04). There were no differences in aesthetic results, both assessed by the patient herself and by the doctor. Statistically significant differences in measures of quality of life were observed in favour of the APBI, both in EORTC QLQ-BR23 and body image scale questionnaires. With a median follow-up of 72 months (6 years), the estimated overall survival at 5 and 10 years was 96.8 and 77.7%, respectively, and disease-free survival at 5 and 10 years was 91.1 and 69.4%, respectively, without statistically significant differences between groups. Discussion APBI is an attractive alternative in candidate patients with initial breast cancer, with benefits in acute toxicity and quality of life and fewer visits to the hospital, without compromising tumor control or survival.


  • Open Access

    Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer

    by Xenia Peñate, Juan Manuel Praena-Fernández, Pedro Romero Pareja, María del Valle Enguix-Riego, Laura Payán-Bravo, Begoña Vieites, Lourdes Gomez-Izquierdo, Javier Jaen Olasolo, Eleonor Rivin del Campo, Jose Carlos Reyes, et al.

    Canonical prefoldin is a protein cochaperone composed of six different subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients.


  • Open Access

    Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain

    by José Expósito, Isabel Linares, Isabel Castillo, Miguel Martínez, Pilar Vargas, Ismael Herruzo, José Antonio Medina, Amalia Palacios, Eloísa Bayo, Francisco Peracaula, et al.

    Around 27,000 new cases of prostate cancer are diagnosed every year in Spain and 5400 die from this disease. Radiotherapy (RT), alone or combined, has proven to be effective as initial treatment in patients with localized disease. Our objective was to evaluate the use of external beam RT (EBRT) in our region, comparing the indication rate and irradiation rate and examining variability in its application among hospitals. We conducted a review of RT guidelines and indication studies for prostate cancer (% expected irradiation). Data were gathered from all twelve public healthcare centers in Andalusia (Spain) on RT-treated prostate cancer patients during 2013 (% actual irradiation) and from nine of the centers on RT discharge reports. Information was classified according to type of hospital, tumor risk category and RT treatment (technique, dosage, volume, toxicity). The estimated RT rate was 67 % (1289/1917), 43 % were aged > 70 years, 44.7 % had ECOG performance status of 0); 44.7 % had high-risk tumors; 57 % underwent RT associated with hormone therapy; 70 % of patients receiving RT were treated with 3D planning (30 % IGRT); and doses were 70–76 Gy in 70 % of cases and >76 Gy in 10.7 %. Acute gastrointestinal and genitourinary toxicities were < grade 2 in 79 and 89 % of patients, respectively. An irradiation rate significantly below the mean for the study was found in four provinces. There was a significant difference among provinces in the distribution of risk groups. Underutilization of EBRT was estimated to be around 30 % in prostate cancer patients, with an elevated variability in irradiation rates among hospitals related to differences in available technology and in the distribution of patients with different risk levels. These data should be a matter of concern to regional health managers, given the negative and measurable impact on the survival of patients.


  • Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature

    by José A. González Ferreira, Javier Jaén Olasolo, Ignacio Azinovic, Branislav Jeremic

    Treatment delays in completing radiotherapy (RT) for many neoplasms are a major problem affecting treatment outcome, as increasingly shown in the literature. Overall treatment time (OTT) could be a critical predictor of local tumor control and/or survival. In an attempt to establish a protocol for managing delays during RT, especially for heavily overloaded units, we have extensively reviewed the available literature on head and neck cancer. We confirmed a large deleterious effect of prolonged OTT on both local control and survival of these patients.


  • Open Access

    Pattern of use of radiotherapy for lung cancer: a descriptive study

    by Isabel Tovar, Jose Expósito, Javier Jaén, Enrique Alonso, Miguel Martínez, Rosa Guerrero, Juan P Arrebola, Rosario Del Moral